Clinical Observation On The Efficacy Of Adefovir Dipivoxil In Patients With Hbeag Positive Chronic Hepatitis B

Background: The Chronic hepatitis B is a social problem witch causes serious harm tothe public health.It is caused by the chronic hepatitis B virus infection. According to theworld health organization reports,Global had about2billion people who have been infectedby infection，350million of them are chronic hepatitis B virus infection。Period of disease，if it can’t be solved timely and effectively, it meybe gradually lead to liver cirrhosis, liverfailure, and even liver cancer, each year about1million people died from the disease[1-2]。Sothe treatment of chronic hepatitis B, the situation is still severe. In recent years, people havedeveloped a variety of antiviral drugs, nucleoside drugs has good curative effect,, so it hasbeen widely used in clinical treatment.Objective: This experiment is using domestic adefovir piece (DingHe) to treat adultwho is chronic hepatitis B patients or cirrhosis,with HBeAg-positive.Through theobservation of the patient laboratory index: liver result (such as ALT, AST, GGT, TBIL,albumin, total bilirubin, indirect bilirubin, direct bilirubin, etc), HBV-DNA, renal function(creatinine, urea nitrogen), routine blood, blood clotting, pancreas function (blood and urineamylase) and adverse reaction[3](such as headache, fever, liver area unwell, upperrespiratory tract infection, diarrhea, vomiting, insomnia, leukopenia, increased amylase, skinrashes, nausea, loss of appetite, renal tubular disease[4]), we can evaluate the effectivenessand safety of the drugs.Methods: This experiment chooses64patients （Including the outpatients andinpatients）who are diagnosised by the laboratory for HBeAg positive of chronic hepatitisB or liver cirrhosis respectively between jul2010and jul2011.4weeks,12weeks,24weeks,36weeks,52weeks,64weeks later after the drug treatment，we will test serum hbv-dna,liver meritorious service (such as ALT, AST, total bilirubin, indirect bilirubin, directbilirubin, GGT, TIBL, albumin, etc), renal function (creatinine, urea nitrogen), routine blood,and pancreatic function (blood and urine amylase), coagulant function index, and monitorpatient adverse reactions closely.Results:1、52weeks later after treatment,51cases (79.7%) get virologic response,13cases (20.3%) have not obtained virologic response.2、Serum HBeAg of14cases (21.8%) patients turns to normal, including eight cases(12.5%) patients experienced HBeAg/resistance-HBe serological transformation.3、ALT of50cases (78%) patients turns to normal.4、Serum HBV-DNA of21cases (32.8%) patients turns to normal.Before and aftertreatment,the two datas had significant differences (P <0.05). We don’t find significantadverse reactions.Conclusion:1、According to adefovir dipivoxil (DingHe) treat the people with HBeAg-positivecaused by chronic hepatitis b,it have a good clinical curative effect. in virology andbiochemistry.2、In the course of52weeks treatment,2cases (3.1%) patients experiences HBV-DNArebound， not detecting the associated resistance mutations.3、The security of adefovir dipivoxil for the peole with HBeAg-positive of chronichepatitis B is good, without any obvious adverse reactions.